Abstract 1378P
Background
The management of non-small cell lung cancer (NSCLC) has transformed over the past decade through the development of immunotherapy and targeted therapies. Our objective was to evaluate the gains in survival in stage IV NSCLC by sociodemographic groups in the United States.
Methods
Patients diagnosed with and treated for Stage IV NSCLC between 2010 and 2020 in the National Cancer Database were studied in 3 eras (2010 - 2013, 2014 - 2017, and 2018 - 2020). Unadjusted survival was assessed by Kaplan Meier and stratified cox analysis was performed to evaluate differences in survival by race and ethnicity.
Results
Overall, 374,273 patients were identified. The median survival was highest across all 3 eras for Asians (12.9, 17.0, and 22.5 months) and the lowest for American Indians/Alaskan Natives (6.9, 6.9, and 9.0 months) (Table). Survival increased for all racial/ethnicity groups across eras, consistent with the development of novel therapeutics, but with considerable differences in the proportionality of gains. For example, between era 1 and 3, Hispanics experienced an 81% increase in median survival, while American Indians/Alaskan Natives experienced a 30% increase (Table). Multivariable Cox models also demonstrated considerable variability in mortality risk over time, favoring groups other than non-Hispanic white patients with the exception of American Indians/Alaskan Natives.
Table: 1378P
| 2010-2013 | 2014-2017 | 2018-2020 | |||||
| Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | % Difference in median survivalEra 3 &1 | |
| Asian | 12.8 | 0.69 (ConclusionsThere has been a dramatic improvement in survival among stage IV NSCLC over the past decade across all race and ethnicity. The rates of improvement in survival were observed to differ across sociodemographic groups, with the Hispanic patients experiencing the highest benefit. Further studies to understand variability in survival gains by type of therapy or by mutation status are warranted to understand the long-term potential disparities in cancer-related mortality. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyD. Boffa. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest. Resources from the same session1773P - Genomic and transcriptomic analysis of chondrosarcomas to explore new potential treatment optionsPresenter: Konstantin Zirov Session: Poster session 06 1774P - Immunological-molecular profiling of chondrosarcoma (ChS)Presenter: Piotr Rutkowski Session: Poster session 06 1775P - Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomasPresenter: Evan Rosenbaum Session: Poster session 06 1776P - Targeting B7H3 biomimetic nanoparticles for strengthening osteosarcoma photodynamic therapy through aggravating DNA damagePresenter: Tianqi Luo Session: Poster session 06 1777P - Molecular profiling from next-generation sequencing (NGS) reveals new potential therapeutic targets in patients with pediatric-type sarcomasPresenter: Anthony Conley Session: Poster session 06 1778P - Clear cell sarcomas (CCS) express Gp100: A novel immune target for a bispecific T cell engagerPresenter: Elise Nassif Haddad Session: Poster session 06 1779P - Deep learning tertiary lymphoid structures detection on HES/H&E slides and association to survival outcome in sarcomaPresenter: Lucile Vanhersecke Session: Poster session 06 1780P - Homologous recombination pathway in sarcomas: A novel opportunity of therapy?Presenter: María del Carmen Garijo Martínez Session: Poster session 06 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||||